LEGISLATIVE BUDGET BOARD Austin, Texas

FISCAL NOTE, 86TH LEGISLATIVE REGULAR SESSION

April 8, 2019

TO: Honorable James B. Frank, Chair, House Committee on Human Services

FROM: John McGeady, Assistant Director Sarah Keyton, Assistant Director

Legislative Budget Board

IN RE: HB3286 by Sheffield (Relating to Medicaid reimbursement for medication-assisted treatment for opioid or substance use disorder.), **As Introduced**

No significant fiscal implication to the State is anticipated in the 2020-21 biennium. The loss of revenue is expected to increase and become significant in future biennia.

The bill would require the Health and Human Services Commission (HHSC) to provide Medicaid reimbursement for medication-assisted opioid or substance use disorder treatment without requiring prior authorization or precertification. The bill would only authorize HHSC to provide reimbursement for the treatments if prescribed by certain providers. According to HHSC, there would be a loss of supplemental vendor drug rebates if the provisions of the bill were implemented because preferred drug list prior authorization could no longer be required. The state share of lost rebates would not be significant in the 2020-21 biennium but would become significant in future biennia.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 529 Health and Human Services Commission

LBB Staff: WP, AKi, LR